A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Trial Profile

A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Etirinotecan pegol (Primary) ; Docetaxel; Eribulin; Gemcitabine; Ixabepilone; Paclitaxel; Vinorelbine
  • Indications Advanced breast cancer; Brain metastases
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, an interim analysis will be performed at 50% of deaths (130 events).
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 09 May 2017 According to a Nektar Therapeutics media release, data from this trial will be presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top